Furosemide vs Placebo in Severe Preeclampsia Postpartum
ConditionSevere Preeclampsia
Trial statusNot yet recruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexFemale
Age14-49
SponsorUniversidad Nacional Autonoma de Honduras
About this trial
This randomized, double-blind, placebo-controlled trial evaluates whether oral furosemide 40 mg, initiated 12 hours postpartum, reduces hospital length of stay compared to placebo (folic acid 5 mg) in postpartum women with severe preeclampsia. Secondary outcomes include need for rescue antihypertensive medications, weight reduction, and metabolic safety (hypokalemia, renal function). A total of 186 participants (93 per arm) will be enrolled across two hospitals in Honduras.
Eligibility criteria
Qualifiers
Signed informed consent (assent for minors 14-17 years with parental/guardian consent)
Confirmed severe preeclampsia (BP ≥160/110 mmHg, or lower BP with thrombocytopenia, hepatic dysfunction, renal insufficiency, pulmonary edema, or cerebral/visual symptoms)
Postpartum (12-24 hours after delivery, vaginal or cesarean)
Hemodynamically stable (no vasopressors for ≥6 hours)
Disqualifiers
Current or chronic diuretic use (before or during pregnancy)
Known allergy to sulfonamides or furosemide
Active febrile illness
Known chronic kidney disease (eGFR <60 mL/min/1.73m²)
Trial design
Treatments tested in this trial
- Furosemide
- Folic Acid 5 MG
Treatment groups
186 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov